Other equities analysts have also recently issued reports about the stock. Deutsche Bank raised shares of Cochlear to a buy rating in a research note on Thursday. Jefferies Financial Group set a $53.00 target price on shares of Cochlear and gave the company a buy rating in a research note on Thursday.
COH opened at A$166.03 ($117.75) on Thursday. Cochlear has a fifty-two week low of A$129.18 ($91.62) and a fifty-two week high of A$192.80 ($136.74). The company has a current ratio of 2.03, a quick ratio of 1.35 and a debt-to-equity ratio of 24.18.
Cochlear Company Profile
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories.
Recommended Story: What is a Derivative?
Receive News & Ratings for Cochlear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cochlear and related companies with MarketBeat.com's FREE daily email newsletter.